{"schemaVersion":"wpf-profile-export-v1","exportedAt":"2026-09-18T15:17:28.864Z","profile":{"slug":"ipamorelin","name":"Ipamorelin","aliases":["Ipamorelin acetate","NNC 26-0161"],"category":"Growth-hormone secretagogue"},"synthesis":{"mechanism":"Ipamorelin is a synthetic pentapeptide growth-hormone secretagogue that activates the ghrelin receptor (GHSR1a). It was designed to stimulate pulsatile growth-hormone release with less ACTH or cortisol stimulation than some earlier secretagogues.","evidence":"Published evidence includes pharmacology, animal studies, small human pharmacodynamic work, and clinical development in postoperative gastrointestinal dysmotility. These data do not establish an approved anti-aging, body-composition, recovery, or performance indication.","safety":"The long-term consequences of repeated GH/IGF-1 stimulation are not established. Potential concerns include glucose dysregulation, fluid retention, headache, appetite effects, endocrine interactions, and uncertain product identity or sterility outside regulated trials.","observationalBoundary":"This corpus separates ipamorelin-specific human and preclinical studies from broader ghrelin-receptor and growth-hormone-secretagogue context.","openQuestions":"Do composition-confirmed preparations provide clinically meaningful benefit for any indication, and what are their long-term metabolic, cardiovascular, endocrine, and malignancy-related safety profiles?"},"completion":{"version":"wpf-profile-v1.0","complete":true,"checks":[{"key":"overview","passed":true,"actual":246,"required":100,"severity":"blocking"},{"key":"evidence_summary","passed":true,"actual":270,"required":100,"severity":"blocking"},{"key":"safety_summary","passed":true,"actual":269,"required":100,"severity":"blocking"},{"key":"archive_boundary","passed":true,"actual":142,"required":75,"severity":"blocking"},{"key":"open_questions","passed":true,"actual":202,"required":75,"severity":"blocking"},{"key":"verified_sources","passed":true,"actual":25,"required":25,"severity":"blocking"},{"key":"reviewed_sources","passed":true,"actual":25,"required":1,"severity":"blocking"},{"key":"chemistry","passed":true,"actual":true,"required":true,"severity":"blocking"},{"key":"regulatory_context","passed":true,"actual":2,"required":2,"severity":"blocking"},{"key":"claims","passed":true,"actual":25,"required":1,"severity":"blocking"},{"key":"claim_traceability","passed":true,"actual":0,"required":0,"severity":"blocking"},{"key":"regulatory_freshness","passed":true,"actual":0,"required":0,"severity":"warning"}],"failures":[]},"chemistry":{"id":"8a146a39692ccf284522c93580fcd748","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","molecularFormula":"C38H49N9O5","molecularWeight":711.86,"aminoAcidSequence":"Aib-His-D-2-Nal-D-Phe-Lys-NH2","smiles":null,"inchi":null,"inchikey":null,"structureImageUrl":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},"evidence":[{"id":"9ac2f2d3370644ca275cb527d1ca0a64","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","title":"A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/41880199/","evidenceTier":"laboratory","summary":"Marketed as more selective and ostensibly safer alternatives, peptides-including growth hormone secretagogues (e.g., Ipamorelin), growth hormone-releasing hormone analogues (e.g., CJC-1295, Sermorelin), and synthetic fragments (e.g., Frag 176-191, KPV)-are promoted for mus …","authors":"Coutinho LFD, DE Oliveira Neves LF, Camilo RP.","publishingOrg":null,"publicationYear":2026,"doi":"10.23736/S0022-4707.26.17773-1","pubmedId":"41880199","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.23736/s0022-4707.26.17773-1","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:ipamorelin:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":63,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":72,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.23736/S0022-4707.26.17773-1","pmid":"41880199","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"805f7cd8c05f9c0a3005cafa50f0bf28","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","title":"Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/41476424/","evidenceTier":"laboratory","summary":"Key peptides evaluated included BPC-157, TB-4, TB-500, CJC-1295 + ipamorelin, tesamorelin, and GHK-Cu. RESULTS: BPC-157 demonstrated potential benefits in tendon and muscle repair, but these findings are largely unvalidated in human trials. ...TB-4 and its derivative TB-50 …","authors":"Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF, Gamradt SC, Weber AE.","publishingOrg":null,"publicationYear":2026,"doi":"10.1177/03635465251357593","pubmedId":"41476424","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1177/03635465251357593","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:ipamorelin:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1177/03635465251357593","pmid":"41476424","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"4b66348329cb17dca35c9dc96b17a141","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","title":"Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/42160466/","evidenceTier":"laboratory","summary":"Regenerative peptides (e.g., body protection compound-157 and thymosin derivatives) and growth hormone axis secretagogues (e.g., CJC-1295, ipamorelin, and tesamorelin) remain investigational, with uncertain safety profiles, product quality concerns, and widespread antidopi …","authors":"Villegas Meza AD, Nocek M, Mitchell BC, Lizarraga M, DeFoor MT, Ruzbarsky JJ, Huard J, Philippon MJ.","publishingOrg":null,"publicationYear":2026,"doi":"10.2106/JBJS.RVW.26.00027","pubmedId":"42160466","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.2106/jbjs.rvw.26.00027","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:ipamorelin:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":63,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":72,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.2106/JBJS.RVW.26.00027","pmid":"42160466","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"806d869d00580f938012bd7e5549cf1c","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","title":"Peptide Supplements and Their Therapeutic Applications in Sports Medicine.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/42578445/","evidenceTier":"laboratory","summary":"PURPOSE: To summarize existing peer-reviewed data on 6 emerging peptides (BPC-157, thymosin beta-4 or TB-500, CJC-1295, MK-677, ipamorelin, and GHK-Cu [copper peptide]) for musculoskeletal recovery and enhancement in animal and human models. ...METHODS: Three independent r …","authors":"Tewari K, Liu TP, Im C, Hamad C, Petrigliano F, Cheung EC, Kremen TJ Jr.","publishingOrg":null,"publicationYear":2026,"doi":"10.1177/03635465261464420","pubmedId":"42578445","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning Peptide Supplements and Their Therapeutic Applications in Sports Medicine.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1177/03635465261464420","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:ipamorelin:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":63,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":72,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1177/03635465261464420","pmid":"42578445","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"e2bc8c130f01436470ab039f96b1edb5","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","title":"Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/41966639/","evidenceTier":"phase_1_2","summary":"Our objective is to present the pharmacological mechanisms, safety profiles, and regulatory status of prominent approved and unapproved peptides marketed direct to patients, including AOD-9604 (anti-obesity drug 9604), BPC-157 (body protection compound 157), CJC-1295, FS-344 (fol …","authors":"Mendias CL, Awan TM.","publishingOrg":null,"publicationYear":2026,"doi":"10.1007/s40279-026-02437-0","pubmedId":"41966639","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes human_interventional evidence concerning Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.","supportNature":"contextualizes","qualification":"Context source concerns a parent peptide, related analog, pathway, detection method, or broader class and must not be treated as direct evidence for the named compound.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1007/s40279-026-02437-0","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:ipamorelin:wave2:2026-09-08","evidenceLane":"human_interventional","extractionPayload":{"limitations":["Context source concerns a parent peptide, related analog, pathway, detection method, or broader class and must not be treated as direct evidence for the named compound."],"studyDesign":"Human interventional or clinical study","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":63,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":45,"replication":45,"designAndBias":68,"populationRelevance":78},"provisional":true},"directCompoundEvidence":false,"relationshipToNamedCompound":"parent_analog_pathway_or_regulatory_context"},"provenancePayload":{"doi":"10.1007/s40279-026-02437-0","pmid":"41966639","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"3bafcea761dcdc072ef5481d641a28af","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","title":"The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/42395176/","evidenceTier":"laboratory","summary":"The agents most commonly encountered in clinical practice and online self-administration protocols include growth hormone-releasing hormone (GHRH) analogues (e.g., sermorelin, tesamorelin, CJC-1295 with Drug Affinity Complex [DAC], CJC-1295 without DAC), growth hormone secretagog …","authors":"Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, RuchaŁa M.","publishingOrg":null,"publicationYear":2026,"doi":"10.3389/fendo.2026.1822475","pubmedId":"42395176","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.","supportNature":"contextualizes","qualification":"Context source concerns a parent peptide, related analog, pathway, detection method, or broader class and must not be treated as direct evidence for the named compound.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.3389/fendo.2026.1822475","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:ipamorelin:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Context source concerns a parent peptide, related analog, pathway, detection method, or broader class and must not be treated as direct evidence for the named compound."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"D","score":49,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":45,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":false,"relationshipToNamedCompound":"parent_analog_pathway_or_regulatory_context"},"provenancePayload":{"doi":"10.3389/fendo.2026.1822475","pmid":"42395176","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"311677af4bf23507315dcad7f311a3e1","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","title":"Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/42123471/","evidenceTier":"laboratory","summary":"This peer-reviewed source examines Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.","authors":"Renke G, Chinellato L.","publishingOrg":null,"publicationYear":2026,"doi":"10.3390/ijms27093890","pubmedId":"42123471","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.","supportNature":"contextualizes","qualification":"Context source concerns a parent peptide, related analog, pathway, detection method, or broader class and must not be treated as direct evidence for the named compound.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.3390/ijms27093890","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:ipamorelin:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Context source concerns a parent peptide, related analog, pathway, detection method, or broader class and must not be treated as direct evidence for the named compound."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"D","score":49,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":45,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":false,"relationshipToNamedCompound":"parent_analog_pathway_or_regulatory_context"},"provenancePayload":{"doi":"10.3390/ijms27093890","pmid":"42123471","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"43c59d5fea0fb5c846c276a20a81a33c","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","title":"Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/41490200/","evidenceTier":"laboratory","summary":"Wound-healing peptides such as BPC-157, TB-500, and GHK-Cu promote angiogenesis, integrin-mediated extracellular matrix remodeling, and fibroblast activation, whereas growth hormone secretagogues like ipamorelin, CJC-1295, tesamorelin, sermorelin, and AOD-9604 activate IGF …","authors":"Rahman OF, Lee SJ, Seeds WA.","publishingOrg":null,"publicationYear":2026,"doi":"10.5435/JAAOSGlobal-D-25-00236","pubmedId":"41490200","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.5435/jaaosglobal-d-25-00236","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:ipamorelin:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.5435/JAAOSGlobal-D-25-00236","pmid":"41490200","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"7ab19f3a1e88e6fc26521c77c190c301","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","title":"Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/42021992/","evidenceTier":"phase_1_2","summary":"Search terms included \"peptide therapeutics,\" \"aging,\" \"gerontology,\" \"healthspan,\" combined with specific peptide names (tirzepatide, epitalon, GHK-Cu, BPC-157, TB-500, Semax, CJC-1295, ipamorelin, bremelanotide). Peer-reviewed articles, clinical trials, regulatory docume …","authors":"Mavrych V, Shypilova I, Bolgova O.","publishingOrg":null,"publicationYear":2026,"doi":"10.3389/fragi.2026.1790247","pubmedId":"42021992","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes human_interventional evidence concerning Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.","supportNature":"contextualizes","qualification":"Compound-specific human evidence remains limited in size, duration, outcomes, or replication.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.3389/fragi.2026.1790247","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:ipamorelin:wave2:2026-09-08","evidenceLane":"human_interventional","extractionPayload":{"limitations":["Compound-specific human evidence remains limited in size, duration, outcomes, or replication."],"studyDesign":"Human interventional or clinical study","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"B","score":76,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":72,"designAndBias":68,"populationRelevance":78},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.3389/fragi.2026.1790247","pmid":"42021992","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"9db677f92d5a5d6fc5a7d31295dc1b62","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","title":"The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/39043357/","evidenceTier":"laboratory","summary":"This study investigated whether ghrelin mimetics, namely anamorelin and ipamorelin, can alleviate weight loss and inhibition of feeding observed during acute and delayed phases of cisplatin-induced emesis in ferrets. The potential of anamorelin to inhibit electrical field …","authors":"Lu Z, Ngan MP, Liu JYH, Yang L, Tu L, Chan SW, Giuliano C, Lovati E, Pietra C, Rudd JA.","publishingOrg":null,"publicationYear":2024,"doi":"10.1016/j.physbeh.2024.114644","pubmedId":"39043357","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/j.physbeh.2024.114644","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:ipamorelin:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1016/j.physbeh.2024.114644","pmid":"39043357","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"d562b956ded8c2b91aa067e271401d64","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","title":"The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/38996787/","evidenceTier":"laboratory","summary":"The objective of this study was to examine the impact of ipamorelin acetate (IPA), a ghrelin agonist, on the reproductive axis of the tilapia Oreochromis mossambicus. ...","authors":"Gouda M, Ganesh CB.","publishingOrg":null,"publicationYear":2024,"doi":"10.1016/j.anireprosci.2024.107550","pubmedId":"38996787","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/j.anireprosci.2024.107550","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:ipamorelin:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1016/j.anireprosci.2024.107550","pmid":"38996787","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"f8b262d449b8a201d11f33dc43858243","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","title":"Attenuation of Visceral and Somatic Nociception by Ghrelin Mimetics.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/32801950/","evidenceTier":"laboratory","summary":"Here, we investigate the efficacy of peripherally restricted (ipamorelin) and a globally active (HM01) selective ghrelin receptor agonist in an experimental model of non-inflammatory visceral hypersensitivity and somatic mechanical allodynia. ...RESULTS: Compared to vehicl …","authors":"N Mohammadi E, Louwies T, Pietra C, Northrup SR, Greenwood-Van Meerveld B.","publishingOrg":null,"publicationYear":2020,"doi":"10.2147/JEP.S249747","pubmedId":"32801950","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning Attenuation of Visceral and Somatic Nociception by Ghrelin Mimetics.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.2147/jep.s249747","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:ipamorelin:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.2147/JEP.S249747","pmid":"32801950","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"564b6faf882ae30bb9d0c25eb87356d6","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","title":"Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/32257855/","evidenceTier":"laboratory","summary":"The GHS that will be discussed include sermorelin, growth hormone-releasing peptides (GHRP)-2, GHRP-6, ibutamoren, and ipamorelin. All are potent GH and IGF-1 stimulators that can significantly improve body composition while ameliorating specific hypogonadal symptoms inclu …","authors":"Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI.","publishingOrg":null,"publicationYear":2020,"doi":"10.21037/tau.2019.11.30","pubmedId":"32257855","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.21037/tau.2019.11.30","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:ipamorelin:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.21037/tau.2019.11.30","pmid":"32257855","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"785816efbf5f8c0a3f84e7af9e923f7b","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","title":"Analysis of new growth promoting black market products.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/29864719/","evidenceTier":"laboratory","summary":"Additionally, three analogues of GHRPs were identified as Gly-GHRP-6, Gly-GHRP-2 and Gly-Ipamorelin, representing the corresponding GHRP extended by a N-terminal glycine residue. The structure of these peptides was characterised by means of high resolution (tandem) mass sp …","authors":"Krug O, Thomas A, Malerød-Fjeld H, Dehnes Y, Laussmann T, Feldmann I, Sickmann A, Thevis M.","publishingOrg":null,"publicationYear":2018,"doi":"10.1016/j.ghir.2018.05.001","pubmedId":"29864719","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning Analysis of new growth promoting black market products.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/j.ghir.2018.05.001","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:ipamorelin:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1016/j.ghir.2018.05.001","pmid":"29864719","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"24b47fbbdc0b6599fbb7eef9ec806176","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","title":"Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/25331030/","evidenceTier":"phase_1_2","summary":"Overall incidence of any treatment-emergent adverse events was 87.5 % in the ipamorelin group and 94.8 % in placebo group. Median time to first tolerated meal was 25.3 and 32.6 h in the ipamorelin and placebo groups, respectively (p = 0.15). LIMITATIONS: This proof …","authors":"Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group.","publishingOrg":null,"publicationYear":2014,"doi":"10.1007/s00384-014-2030-8","pubmedId":"25331030","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes human_interventional evidence concerning Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.","supportNature":"contextualizes","qualification":"Compound-specific human evidence remains limited in size, duration, outcomes, or replication.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1007/s00384-014-2030-8","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:ipamorelin:wave2:2026-09-08","evidenceLane":"human_interventional","extractionPayload":{"limitations":["Compound-specific human evidence remains limited in size, duration, outcomes, or replication."],"studyDesign":"Human interventional or clinical study","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"B","score":74,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":68,"populationRelevance":78},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1007/s00384-014-2030-8","pmid":"25331030","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"3b7e403205b3a62e449dfbe5ad5abd38","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","title":"Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/27186127/","evidenceTier":"laboratory","summary":"The goal of this study was to investigate whether ipamorelin, a synthetic peptidomimetic that acts on the ghrelin receptor, accelerates gastric emptying in a rodent model of gastroparesis induced by abdominal surgery and intestinal manipulation. ...Following abdominal surg …","authors":"Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C.","publishingOrg":null,"publicationYear":2012,"doi":"10.2147/JEP.S35396","pubmedId":"27186127","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.2147/jep.s35396","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:ipamorelin:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.2147/JEP.S35396","pmid":"27186127","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"2273b484b8b669c635e519b0acba45f1","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","title":"Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/19289567/","evidenceTier":"laboratory","summary":"In contrast, repetitive dosing of ipamorelin (0.1 or 1 mg/kg) significantly increased the cumulative fecal pellet output, food intake, and body weight gain. The results suggest that postsurgical intravenous infusions of ipamorelin may ameliorate the symptoms in pati …","authors":"Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B.","publishingOrg":null,"publicationYear":2009,"doi":"10.1124/jpet.108.149211","pubmedId":"19289567","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1124/jpet.108.149211","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:ipamorelin:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1124/jpet.108.149211","pmid":"19289567","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"97092d82bd563045ca7d64fbb172f319","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","title":"Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/19231263/","evidenceTier":"animal","summary":"OBJECTIVES: Growth hormone (GH) reduces the catabolic side effects of steroid treatment via effects on the amino-nitrogen metabolism. Ipamorelin is a synthetic peptide with GH releasing properties. We wished to study the metabolic effects of Ipamorelin and GH on sel …","authors":"Aagaard NK, Grøfte T, Greisen J, Malmlöf K, Johansen PB, Grønbaek H, Ørskov H, Tygstrup N, Vilstrup H.","publishingOrg":null,"publicationYear":2009,"doi":"10.1016/j.ghir.2009.01.001","pubmedId":"19231263","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes animal_in_vivo evidence concerning Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/j.ghir.2009.01.001","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:ipamorelin:wave2:2026-09-08","evidenceLane":"animal_in_vivo","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Animal in-vivo study","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":46,"populationRelevance":25},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1016/j.ghir.2009.01.001","pmid":"19231263","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"2defaf63ca90adfe9bc4ec76f19505c8","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","title":"Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/12168778/","evidenceTier":"animal","summary":"In the Ipamorelin group alone, in vitro treatment with Ipamorelin (10(-8) M), or GHRP 6 (10(-8) M), or GHRH (10(-8) M) for 4 hours, increased the percentage of somatotroph cells, without modifying the ratio of strongly/weakly immunostained GH cells. Basal intracellu …","authors":"Jiménez-Reina L, Cañete R, de la Torre MJ, Bernal G.","publishingOrg":null,"publicationYear":2002,"doi":"10.14670/HH-17.707","pubmedId":"12168778","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes animal_in_vivo evidence concerning Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.14670/hh-17.707","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:ipamorelin:wave2:2026-09-08","evidenceLane":"animal_in_vivo","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Animal in-vivo study","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":46,"populationRelevance":25},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.14670/HH-17.707","pmid":"12168778","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"8c4f082bf787521170144b35f406be9c","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","title":"Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/11162489/","evidenceTier":"animal","summary":"In +/lit and lit/lit mice ipamorelin induced a small (15%) increase in body weight by 2 weeks, that was not further augmented by 9 weeks. GH treatment markedly enhanced body weight in both groups. Ipamorelin also increased fat pad weights relative to body weight in …","authors":"Lall S, Tung LY, Ohlsson C, Jansson JO, Dickson SL.","publishingOrg":null,"publicationYear":2001,"doi":"10.1006/bbrc.2000.4065","pubmedId":"11162489","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes animal_in_vivo evidence concerning Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1006/bbrc.2000.4065","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:ipamorelin:wave2:2026-09-08","evidenceLane":"animal_in_vivo","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Animal in-vivo study","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":46,"populationRelevance":25},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1006/bbrc.2000.4065","pmid":"11162489","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"f3a2de7f91e445696872f6bb9e6f6f1f","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","title":"The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/11735244/","evidenceTier":"animal","summary":"The ability of the growth hormone secretagogue (GHS) Ipamorelin to counteract the catabolic effects of glucocorticoid (GC) on skeletal muscles and bone was investigated in vivo in an adult rat model. Groups of 8-month-old female rats were injected subcutaneously for 3 mont …","authors":"Andersen NB, Malmlöf K, Johansen PB, Andreassen TT, Ørtoft G, Oxlund H.","publishingOrg":null,"publicationYear":2001,"doi":"10.1054/ghir.2001.0239","pubmedId":"11735244","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes animal_in_vivo evidence concerning The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1054/ghir.2001.0239","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:ipamorelin:wave2:2026-09-08","evidenceLane":"animal_in_vivo","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Animal in-vivo study","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":46,"populationRelevance":25},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1054/ghir.2001.0239","pmid":"11735244","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"723cd5922bdc4dbd01b1e009b885f343","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","title":"Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/10373343/","evidenceTier":"animal","summary":"The responsiveness of the pituitary to a provocative i.v. dose of ipamorelin or GHRH showed that the plasma GH response was marginally reduced (P<0.03) after ipamorelin, but unchanged after GHRH. The pituitary GH content was unchanged by ipamorelin treatme …","authors":"Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H.","publishingOrg":null,"publicationYear":1999,"doi":"10.1054/ghir.1999.9998","pubmedId":"10373343","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes animal_in_vivo evidence concerning Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1054/ghir.1999.9998","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:ipamorelin:wave2:2026-09-08","evidenceLane":"animal_in_vivo","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Animal in-vivo study","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":46,"populationRelevance":25},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1054/ghir.1999.9998","pmid":"10373343","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"85647ef8fc9191deac78fd2d0e66514c","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","title":"Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/10496658/","evidenceTier":"phase_1_2","summary":"The ipamorelin-GH concentration relationship was characterized using an indirect response model and population fitting. ...CONCLUSIONS: The proposed PK/PD model provides a useful characterization of ipamorelin disposition and GH responses across a range of doses....","authors":"Gobburu JV, Agersø H, Jusko WJ, Ynddal L.","publishingOrg":null,"publicationYear":1999,"doi":"10.1023/a:1018955126402","pubmedId":"10496658","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes PK evidence concerning Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1023/a:1018955126402","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:ipamorelin:wave2:2026-09-08","evidenceLane":"PK","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Pharmacokinetic study","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"B","score":70,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":60,"populationRelevance":65},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1023/a:1018955126402","pmid":"10496658","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"df379d0a843c551f5cea5a7f6252807e","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","title":"Ipamorelin, the first selective growth hormone secretagogue.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/9849822/","evidenceTier":"laboratory","summary":"The development and pharmacology of a new potent growth hormone (GH) secretagogue, ipamorelin, is described. Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2), which displays high GH releasing potency and efficacy in vitro and in vivo. ...The specificity …","authors":"Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH.","publishingOrg":null,"publicationYear":1998,"doi":"10.1530/eje.0.1390552","pubmedId":"9849822","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes in_vitro evidence concerning Ipamorelin, the first selective growth hormone secretagogue.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1530/eje.0.1390552","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:ipamorelin:wave2:2026-09-08","evidenceLane":"in_vitro","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"In-vitro study","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":58,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":42,"populationRelevance":18},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1530/eje.0.1390552","pmid":"9849822","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"1aeaad8dd4dfc44f083e09919793c634","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","title":"Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/9879640/","evidenceTier":"phase_1_2","summary":"Following i.v. bolus injection, plasma concentrations of the peptides declined biexponentially. Ipamorelin differed markedly from the other peptides investigated, demonstrating a systemic plasma clearance 5-fold lower than that of GHRP-6. Ipamorelin was mainly excre …","authors":"Johansen PB, Hansen KT, Andersen JV, Johansen NL.","publishingOrg":null,"publicationYear":1998,"doi":"10.1080/004982598238976","pubmedId":"9879640","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes PK evidence concerning Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1080/004982598238976","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:ipamorelin:wave2:2026-09-08","evidenceLane":"PK","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Pharmacokinetic study","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"B","score":70,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":60,"populationRelevance":65},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1080/004982598238976","pmid":"9879640","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"}],"regulatory":[{"id":"9991ca61395c20803d5c2bf1580c6dc0","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","jurisdiction":"European Union (EMA)","status":"not_approved","approvedIndication":"No centrally authorized EMA medicine for the named compound was identified in the EMA medicines database as of 8 September 2026.","rationale":"This is a time-bounded review of central EU authorization and does not replace member-state, clinical-trial, pharmacy-compounding, or sports-regulation analysis.","sourceTitle":"European Medicines Agency medicines database","sourceUrl":"https://www.ema.europa.eu/en/medicines","dateChecked":"2026-09-08T19:33:45.384Z","reviewDueAt":"2026-12-07T19:33:45.384Z","enteredById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","publicationStatus":"published","factualObservationId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"ba962aec37de4d3239cfc08d6ba2ac85","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","jurisdiction":"United States (FDA)","status":"not_approved","approvedIndication":"No FDA-approved drug product or therapeutic indication for the named compound was identified in Drugs@FDA as of 8 September 2026.","rationale":"This is a time-bounded database review, not a conclusion about efficacy, safety, compounding law, or approval in another jurisdiction.","sourceTitle":"Drugs@FDA: FDA-Approved Drugs","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/","dateChecked":"2026-09-08T19:33:45.384Z","reviewDueAt":"2026-12-07T19:33:45.384Z","enteredById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","publicationStatus":"published","factualObservationId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"}],"claims":[{"id":"c87be9fa0a9ab423c267c9e095006eb7","claimKey":"ipamorelin:source:41966639","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","claimText":"This source contributes human_interventional evidence concerning Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.","scope":{"evidenceLane":"human_interventional","qualification":"Context source concerns a parent peptide, related analog, pathway, detection method, or broader class and must not be treated as direct evidence for the named compound.","sourceStrengthGrade":"C","sourceStrengthScore":63,"directCompoundEvidence":false,"relationshipToNamedCompound":"parent_analog_pathway_or_regulatory_context"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"826a1b729943112bf47963e991db92d2","claimId":"c87be9fa0a9ab423c267c9e095006eb7","evidenceId":"e2bc8c130f01436470ab039f96b1edb5","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 41966639","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"cd22dd1e0c917cd80238ff9543a908f4","claimKey":"ipamorelin:source:41880199","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","claimText":"This source contributes mechanistic evidence concerning A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":63,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"500042e9991b0cc80668f8d354cb1673","claimId":"cd22dd1e0c917cd80238ff9543a908f4","evidenceId":"9ac2f2d3370644ca275cb527d1ca0a64","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 41880199","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"0ebd9632f28c5930a20480245de385cb","claimKey":"ipamorelin:source:41490200","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","claimText":"This source contributes mechanistic evidence concerning Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"be4517fab35a95d3910924da26af3a09","claimId":"0ebd9632f28c5930a20480245de385cb","evidenceId":"43c59d5fea0fb5c846c276a20a81a33c","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 41490200","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"eddac776f94bb9b2032f5802a4d8cf86","claimKey":"ipamorelin:source:41476424","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","claimText":"This source contributes mechanistic evidence concerning Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"f00c6e87218104c5dae432a297da14f3","claimId":"eddac776f94bb9b2032f5802a4d8cf86","evidenceId":"805f7cd8c05f9c0a3005cafa50f0bf28","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 41476424","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"4fa08a8d7969b51090d29783a1226dba","claimKey":"ipamorelin:source:9849822","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","claimText":"This source contributes in_vitro evidence concerning Ipamorelin, the first selective growth hormone secretagogue.","scope":{"evidenceLane":"in_vitro","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":58,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"50ef2a2085c929a05b726f03fc89eab8","claimId":"4fa08a8d7969b51090d29783a1226dba","evidenceId":"df379d0a843c551f5cea5a7f6252807e","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 9849822","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"54d8529c2723870659e434f445961609","claimKey":"ipamorelin:source:42578445","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","claimText":"This source contributes mechanistic evidence concerning Peptide Supplements and Their Therapeutic Applications in Sports Medicine.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":63,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"6edade6bd00a148cc6d4a6dce573f6b7","claimId":"54d8529c2723870659e434f445961609","evidenceId":"806d869d00580f938012bd7e5549cf1c","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 42578445","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"589b0d9b95fcf48c0ea750e0a243d0f2","claimKey":"ipamorelin:source:42123471","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","claimText":"This source contributes mechanistic evidence concerning Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.","scope":{"evidenceLane":"mechanistic","qualification":"Context source concerns a parent peptide, related analog, pathway, detection method, or broader class and must not be treated as direct evidence for the named compound.","sourceStrengthGrade":"D","sourceStrengthScore":49,"directCompoundEvidence":false,"relationshipToNamedCompound":"parent_analog_pathway_or_regulatory_context"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"0abc14205bdd57212579b8fed5ca2bbe","claimId":"589b0d9b95fcf48c0ea750e0a243d0f2","evidenceId":"311677af4bf23507315dcad7f311a3e1","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 42123471","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"b52a979dc90122737d0c8657f306d6f4","claimKey":"ipamorelin:source:32257855","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","claimText":"This source contributes mechanistic evidence concerning Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"beb5dd1a86cfbcdf6d9a37820d85ca1c","claimId":"b52a979dc90122737d0c8657f306d6f4","evidenceId":"564b6faf882ae30bb9d0c25eb87356d6","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 32257855","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"2b1e29eca8bd49c6092d54039b68a6af","claimKey":"ipamorelin:source:39043357","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","claimText":"This source contributes mechanistic evidence concerning The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"83089f7c8223e8089dda5737368d74f2","claimId":"2b1e29eca8bd49c6092d54039b68a6af","evidenceId":"9db677f92d5a5d6fc5a7d31295dc1b62","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 39043357","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"0d6311a54631d118b3e22190cff0607e","claimKey":"ipamorelin:source:29864719","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","claimText":"This source contributes mechanistic evidence concerning Analysis of new growth promoting black market products.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"04c0b7a75acae5c12abd123626dcc6a6","claimId":"0d6311a54631d118b3e22190cff0607e","evidenceId":"785816efbf5f8c0a3f84e7af9e923f7b","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 29864719","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"94f660d480e851bb55e0132d96e3e28d","claimKey":"ipamorelin:source:42021992","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","claimText":"This source contributes human_interventional evidence concerning Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.","scope":{"evidenceLane":"human_interventional","qualification":"Compound-specific human evidence remains limited in size, duration, outcomes, or replication.","sourceStrengthGrade":"B","sourceStrengthScore":76,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"eda44a6bcf2349159f7735b16267cf47","claimId":"94f660d480e851bb55e0132d96e3e28d","evidenceId":"7ab19f3a1e88e6fc26521c77c190c301","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 42021992","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"d8735c8e2c0804f35e3efe7abb7c66ce","claimKey":"ipamorelin:source:10373343","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","claimText":"This source contributes animal_in_vivo evidence concerning Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.","scope":{"evidenceLane":"animal_in_vivo","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"99f568849fd9c8b94c740a1806c4462b","claimId":"d8735c8e2c0804f35e3efe7abb7c66ce","evidenceId":"723cd5922bdc4dbd01b1e009b885f343","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 10373343","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"9d2f07fe3e3ccc7376497779b8a0217b","claimKey":"ipamorelin:source:32801950","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","claimText":"This source contributes mechanistic evidence concerning Attenuation of Visceral and Somatic Nociception by Ghrelin Mimetics.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"4ecde5ca66abbcd7aa4257566878388e","claimId":"9d2f07fe3e3ccc7376497779b8a0217b","evidenceId":"f8b262d449b8a201d11f33dc43858243","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 32801950","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"4c5222a382be49fc8c990cfa5a9c00c7","claimKey":"ipamorelin:source:19231263","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","claimText":"This source contributes animal_in_vivo evidence concerning Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats.","scope":{"evidenceLane":"animal_in_vivo","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"abb5582928a51ede9ad94f55c9f4a5f4","claimId":"4c5222a382be49fc8c990cfa5a9c00c7","evidenceId":"97092d82bd563045ca7d64fbb172f319","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 19231263","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"ded75356d5ad310d5884c27382d16cfa","claimKey":"ipamorelin:source:42395176","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","claimText":"This source contributes mechanistic evidence concerning The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.","scope":{"evidenceLane":"mechanistic","qualification":"Context source concerns a parent peptide, related analog, pathway, detection method, or broader class and must not be treated as direct evidence for the named compound.","sourceStrengthGrade":"D","sourceStrengthScore":49,"directCompoundEvidence":false,"relationshipToNamedCompound":"parent_analog_pathway_or_regulatory_context"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"f5e68f7b7570b0f1fe3b39def0009af7","claimId":"ded75356d5ad310d5884c27382d16cfa","evidenceId":"3bafcea761dcdc072ef5481d641a28af","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 42395176","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"e73b136eb297a9193ca48458c7ec1a33","claimKey":"ipamorelin:source:10496658","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","claimText":"This source contributes PK evidence concerning Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.","scope":{"evidenceLane":"PK","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"B","sourceStrengthScore":70,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"e4641ed7d0a981d8b7a28fd17d2f3ae9","claimId":"e73b136eb297a9193ca48458c7ec1a33","evidenceId":"85647ef8fc9191deac78fd2d0e66514c","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 10496658","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"e75c7d364ad0265fb0c988d60e337968","claimKey":"ipamorelin:source:12168778","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","claimText":"This source contributes animal_in_vivo evidence concerning Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro.","scope":{"evidenceLane":"animal_in_vivo","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"853ea7329ec76ca0198f924dc11c05d1","claimId":"e75c7d364ad0265fb0c988d60e337968","evidenceId":"2defaf63ca90adfe9bc4ec76f19505c8","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 12168778","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"1c43452dab5e5e1e9fe2105df05ae35f","claimKey":"ipamorelin:source:42160466","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","claimText":"This source contributes mechanistic evidence concerning Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":63,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"2503de70ff6dfd9abad3152fdc5708ae","claimId":"1c43452dab5e5e1e9fe2105df05ae35f","evidenceId":"4b66348329cb17dca35c9dc96b17a141","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 42160466","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"98cfb1b854052c5bb0da4604fa4569b6","claimKey":"ipamorelin:source:38996787","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","claimText":"This source contributes mechanistic evidence concerning The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"5791009bbc622ce09db3101b33489f86","claimId":"98cfb1b854052c5bb0da4604fa4569b6","evidenceId":"d562b956ded8c2b91aa067e271401d64","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 38996787","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"b895acbd4a32d7993ce190f8a132661c","claimKey":"ipamorelin:source:11162489","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","claimText":"This source contributes animal_in_vivo evidence concerning Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues.","scope":{"evidenceLane":"animal_in_vivo","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"101d0226b20ef495e2d50a61ad754a7e","claimId":"b895acbd4a32d7993ce190f8a132661c","evidenceId":"8c4f082bf787521170144b35f406be9c","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 11162489","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"d4c6ede4c254f5a9bce73699d7fdfa16","claimKey":"ipamorelin:source:11735244","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","claimText":"This source contributes animal_in_vivo evidence concerning The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats.","scope":{"evidenceLane":"animal_in_vivo","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"1e0635ed97eeac7732a54941742bc8b2","claimId":"d4c6ede4c254f5a9bce73699d7fdfa16","evidenceId":"f3a2de7f91e445696872f6bb9e6f6f1f","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 11735244","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"92282d13e8c285aff21644224564b6fe","claimKey":"ipamorelin:source:19289567","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","claimText":"This source contributes mechanistic evidence concerning Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"d7ab15a6b8bd4a8e0638aea330661111","claimId":"92282d13e8c285aff21644224564b6fe","evidenceId":"2273b484b8b669c635e519b0acba45f1","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 19289567","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"7b63bc3c4ac8f0e03a9ee8b82a1d9b97","claimKey":"ipamorelin:source:9879640","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","claimText":"This source contributes PK evidence concerning Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption.","scope":{"evidenceLane":"PK","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"B","sourceStrengthScore":70,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"16dd23b08f4acde81ef15c4cf7036dba","claimId":"7b63bc3c4ac8f0e03a9ee8b82a1d9b97","evidenceId":"1aeaad8dd4dfc44f083e09919793c634","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 9879640","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"94456454588a1f37b5e2940e9bf4f60a","claimKey":"ipamorelin:source:25331030","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","claimText":"This source contributes human_interventional evidence concerning Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.","scope":{"evidenceLane":"human_interventional","qualification":"Compound-specific human evidence remains limited in size, duration, outcomes, or replication.","sourceStrengthGrade":"B","sourceStrengthScore":74,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"65448e9308591ab34860d77cffe780f0","claimId":"94456454588a1f37b5e2940e9bf4f60a","evidenceId":"24b47fbbdc0b6599fbb7eef9ec806176","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 25331030","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"794f048ba459d4de7c80182bed6aaae7","claimKey":"ipamorelin:source:27186127","peptideId":"784642c5-02af-431f-9f06-a200532f0d31","claimText":"This source contributes mechanistic evidence concerning Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"a74fdad3fd514082d41313d28f2f850d","claimId":"794f048ba459d4de7c80182bed6aaae7","evidenceId":"3b7e403205b3a62e449dfbe5ad5abd38","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 27186127","createdAt":"2026-09-08T19:33:45.384Z"}]}],"correctionHistory":[],"boundaries":{"observationsAreEvidence":false,"completionIsPublicationApproval":false,"medicalAdvice":false}}